3Daughters, Inc.
Clinical development company developing a frameless, non-hormonal intrauterine drug-delivery platform that uses multiple small magnetic implant units which self-assemble in the uterine cavity, a flexible insertion applicator to reduce insertion steps, and a magnetic retrieval tool for removal. The lead program is in preclinical development with IND preparation and planned first-in-human (Phase 1) clinical studies. The company has completed seed financing and is raising a Series A to support clinical entry and has relocated corporate headquarters to a flexible lab/innovation facility in Baltimore to support scale-up and collaborations.
Industries
N/A
Products
Frameless magnetic intrauterine implant system with insertion/retrieval tools
A non-hormonal intrauterine implant system composed of multiple magnetic units with a local contraceptive coating, plus a flexible insertion applicator and a magnetic retrieval tool; designed to self-assemble in the uterine cavity and permit removal without external strings.
Frameless magnetic intrauterine implant system with insertion/retrieval tools
A non-hormonal intrauterine implant system composed of multiple magnetic units with a local contraceptive coating, plus a flexible insertion applicator and a magnetic retrieval tool; designed to self-assemble in the uterine cavity and permit removal without external strings.
Services
Preclinical development and IND-enabling studies
End-to-end preclinical safety, toxicology, pathology, and analytical testing programs to generate IND-enabling data for intrauterine drug-device products.
Intrauterine frameless implant system and insertion/retrieval tools
Development of an integrated, frameless intrauterine implant system consisting of multiple magnetic implant units with local contraceptive coating, delivered with a flexible insertion applicator and removed with a magnetic retrieval tool.
Regulatory strategy and submission support
Regulatory planning, pathway assessment and preparation of regulatory submissions to enable first-in-human clinical studies.
Investor relations and fundraising support
Capital raising, investor outreach, and partnership development to secure funding for preclinical and clinical milestones.
Preclinical development and IND-enabling studies
End-to-end preclinical safety, toxicology, pathology, and analytical testing programs to generate IND-enabling data for intrauterine drug-device products.
Intrauterine frameless implant system and insertion/retrieval tools
Development of an integrated, frameless intrauterine implant system consisting of multiple magnetic implant units with local contraceptive coating, delivered with a flexible insertion applicator and removed with a magnetic retrieval tool.
Regulatory strategy and submission support
Regulatory planning, pathway assessment and preparation of regulatory submissions to enable first-in-human clinical studies.
Investor relations and fundraising support
Capital raising, investor outreach, and partnership development to secure funding for preclinical and clinical milestones.
Expertise Areas
- Intrauterine drug-delivery and implant systems
- Drug-device combination product development
- Preclinical safety, toxicology and IND-enabling study programs
- CMC and manufacturing scale-up for implantable devices
Key Technologies
- Magnetic self-assembly for implant deployment
- Frameless intrauterine delivery architectures
- Copper-based local contraceptive coatings
- Flexible insertion applicators